source
- Regeneron halts Phase 1/2 uveitis antibody trial after safety concernsRegeneron announced termination of a Phase 1/2 study of its investigational anti-inflammatory antibody REGN7041, which was being evaluated for non-infectious uveitis. The company said the decision…
- Regeneron halts Phase 1/2 uveitis antibody trial over unfavorable risk-benefit profileRegeneron has stopped a Phase 1/2 study of its anti‑inflammatory antibody REGN7041 in non‑infectious uveitis, citing an unfavorable benefit‑risk assessment. The antibody targets CD3 on immune cell…